Onconova Therapeutics (ONTX) Stock Price, News & Analysis

Company Overview

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.67 to $1.01
• 52-Week Range: N/A
• Volume: 1.28 million shs
• Average Volume: 96,681 shs
• Market Capitalization: $20.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

Onconova Therapeutics Stock Analysis - MarketRank™

Onconova Therapeutics scored higher than 19% of companies evaluated by MarketBeat, and ranked 931st out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Onconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Onconova Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Onconova Therapeutics are expected to decrease in the coming year, from ($0.72) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Onconova Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Onconova Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ONTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Onconova Therapeutics does not currently pay a dividend.

Dividend Growth

Onconova Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ONTX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for ONTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.30% of the stock of Onconova Therapeutics is held by insiders.

Percentage Held by Institutions

Only 7.95% of the stock of Onconova Therapeutics is held by institutions.

ONTX Stock Analysis - Frequently Asked Questions

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%.

When did Onconova Therapeutics' stock split?

Shares of Onconova Therapeutics reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST) and Bionano Genomics (BNGO).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 9/19/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ONTX
• CUSIP: N/A
• CIK: 1130598
• Web: www.onconova.com
• Phone: (267) 759-3680
• Fax: 267-759-3681
• Employees: 16
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,960,000.00
• Net Margins: -8,930.97%
• Pretax Margin: -8,930.97%
• Return on Equity: -95.43%
• Return on Assets: -61.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.79
• Quick Ratio: 2.79

Sales & Book Value

• Annual Sales: $230,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 21,000,000
• Free Float: 20,310,000
• Market Cap: $20.90 million
• Optionable: Optionable
• Beta: 1.38